Carlsmed, Inc. (CARL) Price & Analysis

Compare

6 Followers

CARL Stock Chart & Stats

Day’s Range― - ―

52-Week Range$11.81 - $15.20

Previous CloseN/A

VolumeN/A

Average Volume (3M)350.04K

Market Cap

N/A

Enterprise ValueN/A

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)―

Beta0.62

Next Earnings

Aug 28, 2025

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding26,516,273

10 Day Avg. Volume107,957

30 Day Avg. Volume350,036

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$18.40

Price Target Upside42.86% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

Bulls Say, Bears Say

Bulls Say

Market PotentialSpinal fusions for Degenerative Disc Disease, which Carlsmed's products address, are a growing market with approximately 445,000 procedures performed annually in the U.S.

Revenue GrowthCarlsmed is expected to sustain an above-average revenue growth rate as the company increases utilization across an expanding number of trained surgeons.

Technology And InnovationCarlsmed's Aprevo Technology Platform is pioneering a new standard of care in spine fusion surgery with custom 3D printed interbody implants and an AI-enabled surgical planning software.

Bears Say

Commercialization ChallengesCarlsmed is in the early stages of commercialization and needs to sizably increase its sales force, and its cervical implant is not yet commercialized, which carries certain risks.

Market CompetitionRisks include the inability to gain market share against larger spine players with broader portfolios.

Regulatory And Reimbursement RisksPotential changes in reimbursement could weaken hospital economics.

Carlsmed, Inc. News

CVS Health upgraded, Occidental downgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

5d ago

ARX

Carlsmed initiated with a Buy at Truist

Truist initiated coverage of Carlsmed (CARL) with a Buy rating and $18 price target The firm views Carlsmed...

6d ago

CARL

Carlsmed initiated with a Buy at BofA

BofA analyst Travis Steed initiated coverage of Carlsmed (CARL) with a Buy rating and $16 price target The...

6d ago

CARL

Carlsmed initiated with a Buy at BTIG

BTIG initiated coverage of Carlsmed (CARL) with a Buy rating and $21 price target The firm views the...

6d ago

CARL

Carlsmed initiated with an Overweight at Piper Sandler

Piper Sandler analyst Matt O’Brien initiated coverage of Carlsmed (CARL) with an Overweight rating and $18 price target...

6d ago

CARL

Carlsmed initiated with a Buy at Goldman Sachs

Goldman Sachs analyst David Roman initiated coverage of Carlsmed (CARL) with a Buy rating and $19 price target...

6d ago

CARL

Carlsmed’s aprevo implants receive CMS NTAP for cervical fusion procedures

Carlsmed (CARL), announced that in the Hospital Inpatient Prospective Payment Systems Final Rule for fiscal year 2026, the...

22d ago

CARL

Opening Day: Accelerant, McGraw Hill come public

Both Accelerant and McGraw Hill made their trading debut in a busy week for initial public offerings last...

26d ago

Carlsmed announces completion of first aprevo cervical procedure

Carlsmed (CARL) announced the completion of the first aprevo cervical procedure on July 14, 2025 by Joseph Osorio,...

26d ago

CARL

Buy Rating for Carlsmed: Innovative Aprevo Technology and Strong Growth Projections Justify Premium Valuation

Carlsmed, Inc. (CARL) has received a new Buy rating, initiated by Bank of America Securities analyst, Travis Steed....

6d ago

CARL

Carlsmed, Inc. Completes Initial Public Offering

An announcement from Carlsmed, Inc. ( ($CARL) ) is now available. On July 24, 2025, Carlsmed, Inc. announced...

1M ago

CARL

Carlsmed 6.7M share IPO priced at $15 per share

The registration statement for the Carlsmed (CARL), Inc. Initial Public Offering was declared effective and the offering is...

1M ago

CARL

CARL FAQ

What was Carlsmed, Inc.’s price range in the past 12 months?

Carlsmed, Inc. lowest stock price was $11.81 and its highest was $15.20 in the past 12 months.

What is Carlsmed, Inc.’s market cap?

Currently, no data Available

When is Carlsmed, Inc.’s upcoming earnings report date?

Carlsmed, Inc.’s upcoming earnings report date is Aug 28, 2025 which is in 5 days.

How were Carlsmed, Inc.’s earnings last quarter?

Currently, no data Available

Is Carlsmed, Inc. overvalued?

According to Wall Street analysts Carlsmed, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Carlsmed, Inc. pay dividends?

Carlsmed, Inc. does not currently pay dividends.

What is Carlsmed, Inc.’s EPS estimate?

Carlsmed, Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Carlsmed, Inc. have?

Carlsmed, Inc. has 26,516,273 shares outstanding.

What happened to Carlsmed, Inc.’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Carlsmed, Inc.?

Currently, no hedge funds are holding shares in CARL

Carlsmed, Inc. (CARL) Earnings & Revenues

Historic Earnings Reports

CARL Stock 12 Month Forecast

Average Price Target

$18.40

▲(42.86% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"12":"$12","17":"$17","22":"$22","14.5":"$14.5","19.5":"$19.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":21,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$21.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18.4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$18.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$16.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[12,14.5,17,19.5,22],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.6,14.169230769230769,14.738461538461538,15.307692307692307,15.876923076923077,16.446153846153845,17.015384615384615,17.584615384615383,18.153846153846153,18.723076923076924,19.29230769230769,19.861538461538462,20.43076923076923,{"y":21,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.6,13.96923076923077,14.338461538461537,14.707692307692307,15.076923076923077,15.446153846153845,15.815384615384614,16.184615384615384,16.553846153846152,16.923076923076923,17.29230769230769,17.66153846153846,18.03076923076923,{"y":18.4,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.6,13.784615384615384,13.96923076923077,14.153846153846153,14.338461538461539,14.523076923076923,14.707692307692307,14.892307692307693,15.076923076923077,15.26153846153846,15.446153846153846,15.63076923076923,15.815384615384616,{"y":16,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":14.45,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":14.45,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":14.45,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":14.45,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":14.45,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":14.45,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":14.45,"date":1740787200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":14.45,"date":1743465600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":14.45,"date":1746057600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":14.45,"date":1748736000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":14.45,"date":1751328000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":13.6,"date":1754006400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":13.6,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >